The effects of interleukin-10 or TGF-beta on anti-CD3/CD28 induced activation of CD8+CD28- and CD8+CD28+ T cells in allergic asthma

M. Eusebio; L. Kraszula; M. Kupczyk; P. Kuna; M. Pietruczuk

doi:10.54517/jbrha6032

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

The effects of interleukin-10 or TGF-beta on anti-CD3/CD28 induced activation of CD8+CD28- and CD8+CD28+ T cells in allergic asthma

M. Eusebio, L. Kraszula, M. Kupczyk, P. Kuna, M. Pietruczuk

Article ID: 6032
Vol 27, Issue 3, 2013

DOI: https://doi.org/10.54517/jbrha6032

Received: 9 October 2013; Accepted: 9 October 2013; Available online: 9 October 2013; Issue release: 9 October 2013

Abstract

The CD8+CD28- and CD8+CD28+ T cells play a primordial role in peripheral tolerance, but little is known about their implication in allergic asthma. This study was designed to determine the changes in a proportion of human circulatory CD8+ subsets before and after short term culture in the presence of anti-CD3/CD28 and IL-10 or TGF-beta. Flow cytometry analysis revealed increased percentage of CD8+CD28- T cells but decreased percentage of CD8+CD28+ T cells enriched from peripheral blood of adult allergic asthma individuals compared to controls (baseline). In comparison to the baseline, co-stimulation with anti-CD3/CD28 and IL-10 decreased the proportion of CD8+CD28- T cells in severe allergic asthma subjects, whereas it increased this value in mild to moderate asthmatic subjects and controls. Adding TGF-beta decreased the proportion of CD8+CD28- T cells from allergic asthma subjects, whereas it has opposite effects on this subset from controls. IL-10 and TGF-beta had some plethoric effects on FoxP3 expression in anti-CD3/CD28 activated CD8+CD28- T cells. Thus, these findings indicate that a control mechanism involving IL-10 and TGF-beta might be defective in allergic asthma subjects.

Keywords

IL-10;TGF-ß;FoxP3;anti-CD3/CD28;CD8+T cells;allergic asthma

References

Supporting Agencies

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...